Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230122 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3478006 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04230122 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 4 participants.
The verdict
NCT04230122, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. For each participant, the study will last up to about 16 weeks, including screening.
Interventions
- DRUG Placebo - IV
- DRUG Placebo - SC
- DRUG LY3478006 - IV
- DRUG LY3478006 - SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2020-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04230122
The ClinicalTrials.gov registry entry for NCT04230122 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo - IV is the first listed.
NCT04230122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04230122 about?
NCT04230122 is a clinical study titled "A Study of LY3478006 in Healthy Participants". The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. F...
What is the current status of trial NCT04230122?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-02-17. Estimated completion is 2020-06-04.
What interventions are being tested in trial NCT04230122?
The interventions under investigation include: Placebo - IV (DRUG), Placebo - SC (DRUG), LY3478006 - IV (DRUG), LY3478006 - SC (DRUG).
Who is sponsoring clinical trial NCT04230122?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.